Therapy for stage I and stage II non-small cell lung cancer.

摘要: Despite complete resection of what seems to be all evident tumor, one third three quarters patients with stages I and II NSCLC ultimately succumb this neoplasm. Patients who are cured an original or small cell cancer remain at risk for a new primary lung cancer. Although the importance lifelong surveillance is clear, extent timing optimal follow-up undefined. clinicians refer development after treatment clinically discernible sites tumor as "recurrence," it probably more accurate consider these foci "persistence"--that is, locoregional site was not sterilized by surgery, distant implants were present from outset but undetected. data sparse, induction improved adjuvant therapy early may helpful. Much further experience needed. Further study application biologic indicators in addition TNM staging likely will help identify high surgical failure benefit combination treatment.